OTTAWA – A class-action lawsuit against pharmaceutical giant Pfizer Canada over its anti-smoking drug Champix will proceed, an Ontario Superior Court has ruled.
The Ontario court certified the class-action lawsuit in June 2012, but Pfizer sought leave to appeal the certification order.
On Friday, lawyers for the plaintiffs, including Toronto-based firm McPhadden Samac Tuovi LLP, announced a judge has dismissed Pfizer’s appeal.
The plaintiffs allege the drug maker failed to warn Canadians taking the drug that they could suffer psychiatric side effects such as depression, anxiety and suicidal thoughts.
The allegations have not been proven in court.
Pfizer says there is no reliable scientific evidence proving that Champix causes these adverse reactions.
- Life in the forest: How Stanley Park’s longest resident survived a changing landscape
- ‘Love at first sight’: Snow leopard at Toronto Zoo pregnant for 1st time
- Buzz kill? Gen Z less interested in coffee than older Canadians, survey shows
- Carbon rebate labelling in bank deposits fuelling confusion, minister says
Comments